A point mutation in PKCa was originally discovered in a subpopulation of human pituitary tumors characterized by their invasive phenotype, and the same mutation was also seen in some thyroid neoplasms. To investigate the role of this mutation in tumorigenesis, normal and mutant human PKCa cDNAs were overexpressed in Rat6 embryo ®broblasts (R6). When extracts of R6 cells that expressed either the normal or mutant PKCa were assayed in the presence of calcium, phosphatidylserine and the phorbol ester TPA, for phosphorylation of either histone IIIS or the EGF-receptor peptide, both extracts gave similar results. However, the subcellular localization of the two proteins diered. Immunohistochemistry studies indicated that after treatment with TPA normal PKCa mainly translocated to the plasma membrane, but mutant PKCa translocated mainly to the perinuclear region and slightly to the nucleus. Furthermore, the cells that expressed the mutant PKCa displayed a decreased requirement for serum when compared to the cells expressing the normal human PKCa, and they formed small colonies in soft agar. By contrast, the cells expressing the normal human PKCa failed to form colonies in soft-agar. Thus, ectopic expression in rat ®broblasts of this mutant human PKCa sequence alters the growth properties of these cells and, when activated, the mutant PKCa displays aberrant intracellular translocation. Therefore, this mutation in PKCa could contribute to the process of tumor progression in certain human tumors.
Introduction
Protein Kinase Cs (PKCs) constitute an expanding family of phospholipid-dependent protein kinases, with 11 isozymes identi®ed to date in mammals. Their requirements for Ca 2+ , stimulation by phorbol esters and other properties provides a classi®cation into four groups: A/ (a, b1. b2. and g) classical cPKCs Ca 2+ -dependent-B/ (d, e, and Z (L), y) novel nPKCs Ca 2+ -independent-C/ (x and i(l)) atypical PKCs which are Ca 2+ -independent and, in contrast to the cPKCs and nPKCs are not stimulated by diacylglycerol (DAG) or the tumor promoter 12-O-tetradecanoyl phorbol-13-ester (TPA) (For review, see Nishizuka, 1992; Hug and Sarre, 1993) . D/ An additional isoform, PKC m also referred to as PKD, has recently been described (Johannes et al., 1994) . From various lipid second messengers known to activate PKCs, only DAG and PtdPns-4,5-P2 were found to promote PKC m kinase activity (Dieterich et al., 1996) . All of these isoforms are Ser/Thr-speci®c protein kinases activated by second messenger action, and they play a central role in signal transduction.
Ever since the tumor-promoting phorbol esters were shown to activate PKC (Castagna et al., 1982) , numerous studies have focused on understanding the role of this enzyme family in the process of tumorigenesis. Overexpression of the PKC enzymes in dierent cell lines displayed various results depending on the isoform and on the cell type used for the exogenous expression: Rat6 ®broblasts overexpressing PKCb1 show an altered growth regulation (Housey et al., 1988) , and those overexpressing PKCe are completely transformed (Cacace et al., 1993) . Variable results have also been observed for PKCa. NIH3T3 cells overexpressing threefold PKCa protein showed an altered`transformed-like' morphology. They were more refractile with a longer and thinner phenotype and could grow in soft agar (Finkenzeller et al., 1992) , whereas Swiss 3T3 cells overexpressing 10-fold PKCa did not show morphological alterations (Eldar et al., 1990) . In agreement with the later study, Rat6 ®broblasts and Balb/C 3T3 cells overexpressing PKCa by 27-and 18-fold respectively, failed to become tumorigenic and even showed a slight inhibition of growth (Borner et al., 1995) .
However, in spite of these variable phenotypes obtained in dierent cell lines, the observations relating PKCa to tumorigenesis and tumor progression are numerous. Indeed, this isoform has been implicated in several cancer-related processes such as invasion and metastasis (Liu et al., 1994; Mapelli et al., 1994; Ways et al., 1995) and multidrug resistance (Ahmad and Glazer, 1993; Yu et al., 1991) .
In human astrocytomas, PKCa immunoreactivity is elevated within the tumor cells in comparison with surrounding brain tissue, and clearly distinguishes the invading tumor cells from normal cerebellar tissue (Benzil et al., 1992) . Antisense to PKCa inhibits cell proliferation in vitro, and the tumorigenicity in vivo in nude mice of a human glioblastoma cell line (Ahmad et al., 1994) . Furthermore, the microinjection of antibodies against PKCa inhibits the cell growth and dierentiation of neuroblastoma cells (Leli et al., 1992) .
Alterated forms of PKCa have also been observed in two cell lines. A smaller than expected PKCa was found in a small lung carcinoma cell line (57 Kd instead of 80 Kd) probably resulting from an aberrant posttranslational processing of the protein (Jones et al., 1994) . And a tumor-speci®c deletion within the gene encoding PKCa was found in a primary melanoma cell line (Linnenbach et al., 1988) .
Recently a mutant of PKCa has been discovered in human pituitaries tumors and shown to be present only in a subpopulation of tumors characterized by their invasive phenotype (Alvaro et al., 1993) . The mutation is located in the V3 hinge region separating the catalytic from the regulatory domains of the enzyme (at position 294 of the amino acid sequence) and leads to the substitution of an aspartic acid by a glycine. The presence of this somatic mutant is not restricted to pituitary tumors and has been also detected in human thyroid neoplasms including adenomas and a follicular carcinoma (Prevostel et al., 1995) .
In order to analyse the biological properties of this PKCa mutant, and determine its possible role in tumorigenesis, normal (hPKCa-wt) and mutant human PKCa (hPKCa-mut) were overexpressed in Rat6 embryo ®broblasts using retrovirus mediated transduction (Cacace et al., 1993) . We found that the mutant PKCa has the same catalytic activity as PKCa-wt when using EGF receptor peptide or histone IIIS as substrates. However, the morphology of the R6-mutPKCa cells upon TPA treatment are dierent from the R6-wt-PKCa cells, as is the subcellular localization of the mutant protein. Expression of the mutant confers new growth properties to the cells. It decreases the requirement of the cells for serum growth factors and the cells form small colonies in soft agar.
Results

Generation of Rat6 ®broblasts that stably overproduce hPKCwt and hPKCmut
After retroviral infection and following selection in puromycine-containing medium, 40 dierent clones each of hPKCa-wt, and hPKCa-mut vector-derived cell lines were isolated, expanded and designated as R6-PKCa-wt and R6-PKCa-mut no. 1 ± 40. As controls, clones containing only the pBabe vector derived sequences were generated and were designated R6-pBabe no. 1 ± 20. In order to determine the level of PKCa expression, total cellular protein was collected from 10 clones each of R6-PKCa-wt, R6-PKCa-mut, and with the vector control pBabe and examined by Western blot using a polyclonal PKCa antibody MC5 (Amersham) directed against a sequence of the V3 region of the enzyme (residues 312-323). This antibody can also recognize the b isoforms but Rat6 cell lines do not contain the b isoforms (Borner et al., 1992a,b) . The MC5 antibody recognizes two bands of 80 kDa and 50 kDa. The higher molecular weight band corresponds to the native PKCa. The lower molecular weight band corresponds to the catalytic fragment of the enzyme generated by the proteolytic degradation of PKCa. The 50 kDa fragment is more prominent in R6-PKCa-mut extracts than in R6-PKCa-wt extracts at the same range of overexpression suggesting that the mutant PKCa is more susceptible to degradation (Figure 1) .
Two clones, R6-hPKCa-mut no. 29 and no. 32 were selected for analysis. They expressed around 20 times the protein (624 and 619 respectively), which is consistent with the maximum increase in PKCa expression found in pituitary tumors (Alvaro et al., 1992 (Alvaro et al., , 1993 . Two R6-hPKCa-wt clones were also selected for analysis, no. 2 and no. 6 that showed a 40-fold and 17-fold overexpression respectively to see the result of overexpression of the protein in the same and higher range than the R6-hPKCa-mut clones. A vector control clone, R6-pBabe no. 2, was randomly picked and analysed in parallel with the four other clones.
The PKC activity is identical for both enzymes PKCa-wt and -mut catalytic activities were measured for the R6-PKCa-wt overproducing clones no. 2, no. 6 and for the R6-PKCa-mut overproducing clones no. 29, no. 32. The assays were performed with dierent concentrations of partially puri®ed enzyme (0.1 ± 3 mg/110 ml of reaction buer) and showed that the catalytic activity is similar for both wt and mut enzymes at all concentrations (data not shown) using the epidermal growth factor receptor (EGF-R) peptide substrate which has been previously used in this type of assay (Housey et al., 1988) or the histone III-S which was used in the assays of our previous paper (Alvaro et al., 1992) . For further experiments, the enzyme activity has been tested with a concentration of 1 mg protein (obtained after partial puri®cation of the enzyme) per 110 ml of reaction buer using the EGF-R peptide. Figure 2 shows that using partially puri®ed cell extracts, overexpressed PKCa-wt and PKCa-mut proteins displayed similar enzymatic properties in vitro and similar responses to all combinations and concentrations of the cofactors Ca 2+ , phospholipid and TPA. (Figure 3d ± g ). When cells were stimulated for 10 min with TPA, PKCa-wt was translocated to the plasma membrane as expected ( Figure 3e ). Staining was discontinuous. By contrast, under the same conditions, R6-PKCa-mut cells exhibited very weak membrane labeling ( Figure 3h ). A residual staining remained around the nuclei which also appeared slightly stained as compared to the nuclei from PKCa-wt transfected cells. Staining at the membrane was also dierent from that of the cells transfected with PKCa-wt: it appeared as a thin, weakly stained and continuous line. After 1 h of TPA treatment (Figure 3f ± i), dierences were even more pronounced. Staining at the membrane of cells transfected by PKCa-wt was still present although a little less prominent, and a rather strong staining was present around the nucleus in a`half-moon' shape. By contrast, staining of the cells transfected with PKCamut was entirely concentrated in`vesicle-like' structures around the nucleus. In control cells, labeling was undetectable (Figure 3a ± c).
After 90 min and 120 min TPA treatment (data not shown), PKCa-wt labeling was less prominent both at the membrane and around the nuclei but otherwise similar to the labeling observed after 60 min TPA treatment. Under identical conditions, staining of the cells transfected with PKCa-mut was still entirely concentrated in`vesicle-like' structures, although these vesicles were less numerous. Plasma membranes were not stained.
Mutant PKCa overexpressors exhibit dierent growth control than that of the wt overexpressors Dierent parameters related to growth and morphology of the cells have been examined. In the standard conditions, with medium containing 10% calf serum and without TPA treatment, all types of cells presented the same¯at and fusiform morphology ( Figure 4 ) and the same growth curve (Table 1) . R6-PKCa-mut overexpressing cells did not display morphologic evidence of transformed foci, and they were contact inhibited as were R6-PKCa-wt overexpressing cells, and R6-pBabe control cells. However, under serum starvation (0.1% calf serum in the medium), whereas the R6-PKCa-wt overexpressing cells showed growth inhibition compared to the parental R6 or the vector control R6-pBabe expressing cells, the PKCa-mut overexpressing cells continued to grow nearly as in 10% serum.
The doubling time of the R6-PKCa-mut cells was 20 h compared to 100 h for the R6-PKCa-wt cells. These results indicate that PKCa-mut overexpression decreases growth factor dependency. R6-hPKCa-mut cells were also able to survive 2 weeks in serum-free medium, whereas the control cell lines and R6-hPKCawt cells died in these conditions (data not shown).
Under TPA treatment, all types of cells underwent a morphological change. The control cells became more rounded and refractile to light, but by 24 h they appeared undistinguishable from the untreated control cells. The R6-hPKCa-mut overexpressors underwent the same morphological changes. However, the R6-hPKCa-wt cells became stretched and much more refractile than the other cells, and did not come back to their original morphology after 24 h (Figure 4) .
The expression of the other isoforms present in Rat6 ®broblasts, PKCe, PKCd and PKCz (Borner et al., 1992a,b) have been analysed by Western blot and failed to show any dierence in their expression between R6-pBabe, R6-PKCa-wt and R6-PKCa-mut overexpressor cell lines (data not shown). Therefore, as the expression of the other PKCs are constant, the dierences seen between wt and mut PKCa are not due to a dierence of endogenous isoforms.
Tumorigenic activity in soft-agar and nude mice Table 1 shows that, in soft-agar, the R6-PKCa-mut cells displayed a slight anchorage-independence as they could form small colonies. The control cell line and the R6-PKCa-wt were unable to grow. There was no dierence between plus and minus TPA treatment.
None of the mice injected with either R6-PKCa-mut, R6-PKCa-wt or the control cell lines showed the formation of a tumor (Table 1) .
Discussion
Recently, a mutant PKCa has been described in human invasive pituitary tumors and in thyroid neoplasms and PKCa-mut total activity using the EGF-receptor peptide substrate. Speci®c activity is reported as the amount of incorporation of 32 P into the substrate per min/mg of enzyme. The reactions have been performed in presence or absence of 80 mM PhosphatidylSerine (PS), 100 ng ml 71 TPA, and 0.6, 1 or 6 mM calcium (Ca 2+ ). The enzymes used in the reaction were partially puri®ed by DEAE columns. After prui®cation, an equal amount of protein has been loaded on a gel, and blotted on a membrane incubated with a PKCa antibody. The respective PKCa-wt and -mut bands were quanti®ed by scanner, and this gave a corrective factor representative of the dierent expression between both enzymes. This factor allowed to correct the amount of total protein used in the enzymatic reaction, in order to use an equal amount of enzyme. Values represent the mean of three independent assays, and are considered as the experimental value minus the`bland value' obtained without any activator (Alvaro et al., 1993; PreÂ vostel et al., 1995) . The goal of this work was to characterize the biochemical properties of this enzyme mutant, its phenotypic eects on cells where it has been stably overexpressed, and to assess if it could be implicated in tumorigenesis or tumor progression.
The mutant PKCa protein results from the substitution of an aspartic acid by a glycine in position 294 of the protein sequence, in the V3 hinge region separating the regulatory domain from the catalytic domain. The amino acid sequence of this region is highly variable from one PKC isoform to the other and contains sequences important for PKC functions. We formulated our experimental hypothesis based on the putative functions of this region of PKC. In particular, the PKCa V3 region contains a putative Ca 2+ -binding site described by Parker et al. (1986) . PKCa is a Ca 2+ -dependent protein, meaning that a dysfunction in Ca 2+ binding could alter the kinase function, resulting either in a constitutively active or inactive form of the enzyme. However, as assessed by the capacity of normal and mutant PKCa to phosphorylate the EGF-R peptide or Histone-IIIS in vitro, the catalytic activity of both enzymes is the same regardless of the presence and the concentration of activators used in the assay. Thus the mutant enzyme seems to be activated identically to the wild-type enzyme and calcium can probably correctly interact with the mutant enzyme.
If the phenotypic dierences observed between the overexpressor cell lines are not due to a dierence in PKC activity, two non exclusive hypothesis can thus be raised: the PKCa mutant might exert its eects because of a dierent turnover rate of the protein, or because of an altered substrate recognition as compared to the wild-type enzyme.
The V3 region contains calpain degradation sites at positions 310, 317 and 325 (Kishimoto et al., 1989) . Activation of the 80 kDa enzyme is followed by downregulation involving proteolytic degradation by calpain of PKC into two fragments of 30 and 50 kDa, followed by a complete degradation of the kinase (Kishimoto et al., 1989) . The mutation could interfere with the calpain-mediated degradation resulting in either a reduced or a higher rate of degradation. In our experiments, degradation of mutant PKCa was higher than that of the wild-type as assessed by the presence of the 50 kDa fragment (Figure 1 ). This degradation was avoided by constantly adding the protease inhibitor PMSF in the buers, which is not necessary for wild-type PKCa known to be very resistant to degradation as compared to other PKC isoforms. Images were obtained using a confocal krypton/argon mixed gas laser scanning microscope (MCR 600 BIORAD). Excitation was at 568 nm for rhodamine. Fluorescent images taken in an equatorial plane (de®ned as the midpoint between the top and the botton of the cell) were digitalized, and pseudocolor images were generated by using arbitrary colors. Overexpressor cells ± (a) pBabe control minus TPA; (d) PKCa-wt minus TPA; (g) PKCa-mut minus TPA; (b) pBabe plus TPA 10 min; (e) PKCa-wt plus TPA 10 min; (h)) PKCa-mut plus TPA 10 min; (c) pBabe plus TPA 60 min; (f) PKCa-wt plus TPA 60 min; (i) PKCa-mut plus TPA 60 min
These results suggest that mutant PKCa could be sensitive to a general degradative process similar to that observed for other PKC V3 domain mutants (Junco et al., 1994; Parker et al., 1995) . The third identi®ed sequence in the V3 region is a nuclear targeting sequence (Mochly-Rosen et al., 1991; James and Olson, 1992) . A modi®cation close to this sequence could result in altered subcellular localization. Immunocytochemistry showed that, whereas both normal and mutant PKCa have the same diuse cytoplasmic localization in the unstimulated cells, dierences were observed under TPA stimulation.
After 10 min of TPA treatment, PKCa-wt was translocated as expected to the plasma membrane, the staining appearing discontinuous, while in the PKCamut overexpressors, membrane staining was very weak. A residual staining was present around the nucleus which also appeared slightly stained, signifying a possible nuclear translocation of PKCa-mut. After 60 min TPA treatment, the dierences were even more pronounced. The R6-PKCa-wt cells exhibited a residual membrane labeling associated with a strong perinuclear staining resembling that of PICK1 (a PKCa-binding protein) (Staudinger et al., 1995) Control Rat6-pBabe no. 2, PKCa-wt no. 2, and PKCa-mut no. 29 were seeded at 5610 5 cells per 10 cm plate. Culture were refed the next day, treated with 100 ng ml 71 for 24 h and photographed after 15 mn, 60 min, and 24 h post-addition of TPA. Magni®cation, 1006. (a±d) R6-pBabe vecteur control cell line: (e ± h) PKCa-mut overexpressor cell line; (i ± l) PKCa-wt overexpressor cell line. a-e-i: minus TPA; b-f-j: plus TPA 10 min; c-g-k: plus TPA 60 min; d-h-l: plus TPA 24 h whereas the R6-PKCa-mut cells show a granulated staining around the nuclei. The mutation we have been studying in this paper could therefore interfere with the subcellular targeting signals of PKCa by unmasking targeting sites, and by modifying the anity of the enzyme towards its binding-proteins (and/or subtrates). This would result in the altered translocation of mutant PKCa that we have observed. The two enzymes may therefore have dierent substrates as they are dierentially compartmentalized, and thus may mediate distinct cellular functions in vivo. We are currently examining if the two enzymes display any dierences in substrate speci®city or binding proteins.
Activated PKC may tanslocate to speci®c points of the plasma membrane such as focal contacts , tight junctions (Stuart and Nigam, 1995) , or to dierent locations in the cell such as the Golgi apparatus (Lehel et al., 1995) , the perinuclear region and the nucleus Buchner, 1995; Olson et al., 1993) . The discontinuous staining of the membrane after translocation of normal activated PKCa could re¯ect translocation to focal contacts as already reported in ®broblasts (Borner et al., 1995) . By contrast, the absence of translocation of mutant PKCa to plasma membranes after TPA treatment is unexpected and could have three explanations: (1) the presence of the mutant PKCa induces changes in the organization of focal contacts; (2) the mutation leads to a dierent subcellular translocation and (3) the mutant no longer has the capacity to interact with proteins associated with focal contacts such as vinculin or talin, known to be PKCa substrates.
Subcellular localization of PKCa has been shown to be dierent in transformed cells. A study of immortalized and SV40-transformed derivatives of primary cultures of renal proximal tubule epithelial cells showed PKCa localized to cell junctions in normal but not transformed cells (Dong et al., 1993) . Likewise, immuno¯uorescence studies demonstrated that PKCa is concentrated in focal contacts of REF 52 rat embryo ®broblast cells but not in their SV40-transformed derivatives (Hyatt et al., 1990) . A comparison of PKC levels and localization in normal and progressively (4 steps) transformed REF 52 con®rmed that changes in PKCa location rather than content was an early event in cell transformation .
In any case, whatever the origin of the dysfunction in PKCa is, the cells expressing PKCa-mut have a modi®ed phenotype as compared to control cells or to the PKCawt transfected cells. PKCa-wt overexpression increases the dependence of R6 cells on growth factors consistent with a previous report (Borner et al., 1995) , whereas PKCa-mut overexpression decreases this dependence. Indeed, when cells are grown in 0.1% serum, doubling time of the cells expressing the mutant is only slightly aected as compared to that in 10% serum, whereas doubling time of the control cells or of the cells expressing normal PKCa increases drastically, which is in agreement with a previous report (Borner et al., 1995) .
The cells are also dierent morphologically. Under TPA treatment, R6-PKCa-mut overexpressing cells, like the control cells, returned to their original morphology after 24 h, whereas R6-PKCa-wt overexpressing cells are still rounded and refractile, re¯ecting modulation in the cytoskeleton structure. The most likely hypothesis is that the induced morphological changes under TPA are the consequence of a membrane translocation which does not occur normally in the cells transfected with the mutant PKC.
The morphological changes of the R6-PKCa-mut cells were not correlated to a major transformed phenotype. R6-PKCa-mut expressing cells could grow in soft-agar in contrast to control cells or to R6-PKCawt expressing cells. But cloning eciency was weak as compared to that of PKCe for instance. When injected in the nude mice, the R6-PKCa-mut gave no tumors, as the other cell lines, indicating that the presence of the D294G mutation in PKCa does not confer an advantage to the cells as far as transformation is concerned. However, the PKCa mutation has been evidenced in invasive pituitary tumors. Thus, the PKCa mutant could be implicated in the progression of the tumor and not in its initiation.
Taken together, these results indicate that the D294G point mutation in the PKCa sequence 
Materials and methods
Expression vector construction and directed mutagenesis
From the normal PKCa human (hPKCa-wt) sequence (Finkenzeller et al., 1990) , PCR-mediated mutagenesis was used to create the mutant PKCa. Speci®cally, a`mutation' 5'-primer ± (871-920) 5'-gaaggtgagtactacaacgtacccattccggaagggggcgaggaaggaaa-3' was designed which would incorporate the point mutation found in pituitary tumors at position 908 (Alvaro et al., 1993) . This mutation was created in the oligonucleotide by substitution of an adenosine by a guanine. The`selection' 3'-primer (1788-1820) 5'-cggaagaaggcatgctctctgacgtccctctc-3' was synthesized with an Aat II restriction site which is not in the hPKCa-wt sequence, and was created by the substitution of a guanine by a cytosine at position 1800. After PCR, using the hPKCa-wt as a template, a 930 bp fragment has been puri®ed and digested by ScaI and SphI whose sites are in the oligonucleotides used in the reaction. This was then done into the corresponding sites with the hPKCa-wt. The selection of mutant clones was based on the Aat II enzyme site present in the`selection' 3'-primer used in the PCR reaction. This site is surrounded by an upstream EcoNI site at position 1133, and a downstream SphI site at position 1806. After isolating the positive`mutant-PKCa' clones, the Aat II site was then removed from the sequence by replacing the¯anking EcoNI-SphI fragment from the Aat II-mutant hPKCa with the normal hPKCa, and screening for loss of the Aat II site. The resulting cDNA was sequenced to con®rm the incorporation of the mutation at position 908, and was then designated hPKCa-mut. This cDNA has been used in further experiments of viral infection for stable overexpression.
The method used to generate R6 wild-type human PKCa and mutant PKCa overproducing cell lines has been previously used in our laboratory to generate Rat 6 embryo ®broblasts (R6) cell lines that stably overproduce cPKCb1 and nPKCe (Housey et al., 1988; Cacace et al., 1993) . Brie¯y, the full length cDNA encoding hPKCa-wt (Finkenzeller et al., 1990) and hPKCa-mut were cloned directionally into the multiple cloning site of the retroviral expression vector pBabe (Markowitz et al., 1990; Morgenstern and Land, 1990) . This vector contains the viral long terminal repeats from the Moloney murine leukemia virus, a puromycine resistance gene (controlled by the simian SV40 virus promoter) and encapsidation sequences. The pBabe-PKCa constructs were transfected by the calcium phosphate precipitation technique into the amphotropic GPAM 12 cell line (Markowitz et al., 1990) . GPAM12 cell lines are NIH3T3 derivatives that contain a helper virus that allowed the generation of defective Moloney murine leukemia virus particles which were then used to infect early passage R6 cells.
Puri®cation and assay of PKC activity from tissue culture cells
The total PKC activity (membrane-associated plus cytosolic) present in cultured cells was determined after partial puri®cation of cellular extract as follows. Two 10 cm plates of con¯uent cells were washed three times with 10 ml of ice-cold PBS, and then 0.5 ml of homogenization buer (20 mM Tris pH 7.5, 5 mM EDTA pH 8, 10 mM EGTA pH 7.5, 15 mM b-mercaptoethanol, 0.2% Triton X100, 1 mg/ml leupeptine, 0.5 mg/ml aprotinin, 0.25 mM PMSF) was added. The cells are scraped from the plates, passed through a 21 g needle, pooled and transferred to a 15 ml disposable polystyrene tube. After 15 min on ice, the tubes were centrifuged at 1500 g for 10 min at 48C.
The supernatant was either used crude for Western blot or loaded on a DEAE column to the puri®ed PKC as described previously (Borner et al., 1991) .
Antibody and immunoblot analysis
Equivalent amounts of total protein were resolved by 8% SDS ± PAGE, transferred to Immobilon-P (Millipore), and immunoblotted with a speci®c antibody, MC5 (Amersham), directed against the V3 region (residues 312-323) of PKCa at a dilution of 1:500.
PKC activity assays
PKC activity was determined as the amount of 32 P incorporated into an epidermal growth factor receptor (EGF-R) peptide substrate by a partially puri®ed PKC preparation (Housey et al., 1988) .
The assays have been performed in the absence or presence and in all of the combinations of: dierent concentration of partially puri®ed enzyme (0.1-0.3-0.5-0.8-1-3 mg/110 ml of reaction buer), dierent concentration of two subtrates: 100 mg/ml of EGF-R substrate (good substrate) or 150 ± 300 mg/ml of histone III-S substrate (poor substrate); dierent concentration of calcium (6 mM, 1 mM, 0.1 mM); 80 mM PhosphatidylSerine; 100 ng/ml TPA.
Assays of growth in monolayer culture and in soft agar
Cells were seeded at a density of 10 4 cells per 35 mm plate in 3 ml of DMEM plus 10% calf serum. Twenty-four hours later, cells in duplicate plates were trypsinized and counted. This day is designed as day 0. The remaining cultures were then grown in the respective medium (plus or minus TPA at 100 ng/ml; 10% or 0.1% calf serum) for 11 days, with fresh medium changes every other day. Cells per plate were then determined in duplicate every 2 days during the remainder of the growth curve. Each experiment has been performed twice. The results obtained were analysed for exponential doubling time and saturation density.
To assess growth in soft agar (anchorage independence), 10 4 cells were resuspended in 2 ml of 0.33% Noble Agar in 16DMEM containing 10% fetal calf serum and overlayed above a layer of 2 ml of 0.5% Noble Agar in the same medium on 35 mm plates. The cells were overlaid with 16DMEM-10% fetal calf serum every 4 days. After 30 days, colonies were stained with the vital stain 2-(p-iodophenyl)-5-phenyltetrazolonium chloride hydrate for 24 h at 378C in an incubator with 5% CO 2 , and the number of colonies were counted under a microscope. The data are expressed as cloning eciency, i.e. number of colonies greater than 0.012 mm per plate times 100 divided by the number of cells originally seeded per plate.
Tumorigenicity assays
Cells were grown, trypsinized, and washed extensively with phosphate-buered saline (PBS). The cells were resuspended at a density of 10 7 cells per 200 ul of PBS. Nude mice were injected subcutaneously at two sites with 10 7 per site and sacri®ced 2 months later.
PKC detection by immunocytochemistry
Cells are seeded at 10 4 per 35 mm dish on a 20620 coverslip in 1.5 ml DMEM and grown for 24 h. The cells were washed quickly three times with PBS, and ®xed for 1 min with formaldehyde 3% (v/v) in a medium containing 80 mM Pipes pH 6.5, 5 mM EDTA, 2 mM MgCl 2 and then for 8 additional min with formaldehyde 3% (v/v) in 100 mM sodium borate pH 11. Cells were then incubated in PBS containing 0.1% (w/v) sodium borohydride, washed, permeabilized by incubation in PBS supplemented with 0.2% Triton X-100, incubated overnight at 48C with the anti-PKCa antibody (UBI), washed and further incubated for 60 min at room temperature with a secondary antibody. This anti-PKCa antibody is a monoclonal antibody raised against PKCa puri®ed from rabbit brain cytosol. It does not recognize PKCb or g or d or e or z (Leach et al., 1988) . After washings, cells were post-®xed for 20 min with 3% formaldehyde in PBS and incubated in the presence of 50 mM NH4C1 for 10 min. The coverslips were mounted in 1,4-Diazabicyclo-(2.2.2) octane, 100 mg/ml in PBS containing 50% glycerol. Images were obtained using a confocal krypton/argon mixed gas laser scanning microscope (MRC 600 BIORAD).
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